Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence
CADTH
Record ID 32014000154
English
Authors' recommendations:
Patients with chronic hepatitis C (CHC) who are null responders to previous peginterferon/ribavirin (PR) therapy may benefit from telaprevir-PR triple therapy. There is no RCT data on this population for boceprevir (BOC)-PR triple therapy. At present, there is no evidence to determine the clinical benefit (in terms of sustained viral response) and harm of adding BOC or TP to PR therapy in patients with recurrent hepatitis C virus who have undergone a liver transplant.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/jun-2013/RC0454%20Hep%20C%20Special%20Populations%20draft%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Hepatitis C, Chronic
- Protease Inhibitors
- Liver Transplantation
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.